We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Life Sciences

  • September 13, 2018

    Boehringer Snags Austrian Biopharma Co. In $245M Deal

    Germany-based Boehringer Ingelheim is taking over an Austrian biotechnology company that focuses on developing cancer treating immunotherapeutics in a $245 million deal, the companies announced Thursday.

  • September 13, 2018

    Allergan Looks To Keep CEO's Tribal Patent Docs Out Of MDL

    Documents from Allergan Inc.’s CEO and general counsel on a deal transferring patents to a Native American tribe are at best “marginally relevant” to multidistrict litigation accusing the company of illegally delaying a generic version of dry-eye medication Restasis, the drugmaker told a New York federal judge Wednesday.

  • September 13, 2018

    Deals Rumor Mill: Meituan Dianping, Takeda, Adobe Systems

    Chinese online services platform Meituan Dianping has raised roughly $4.2 billion in its IPO, Takeda is considering a sale of Shire assets in the wake of its multibillion-dollar acquisition of the drugmaker, and Adobe Systems is interested in buying marketing software firm Marketo.

  • September 13, 2018

    Trump Not In A Hurry To Broker Trade Peace With China

    President Donald Trump said Thursday that he is not rushing to hold new trade talks with Beijing as he signaled a willingness to forge ahead with his aggressive enforcement push that threatens to hit every product imported from China with hefty tariffs.

  • September 12, 2018

    Two Lidoderm Class Action Deals Worth $271M Get Final OK

    A California federal judge on Wednesday approved “excellent” settlements ending claims that Teikoku, Endo and Actavis violated antitrust laws by stalling the release of a generic form of the Lidoderm pain patch, finalizing a $104.75 million deal with end payors and a $166 million deal with direct purchasers, including a combined $85.6 million in attorneys’ fees.

  • September 12, 2018

    SEC Claims Mass. Broker Lied To Short Drug Co. By $1.3M

    The U.S. Securities and Exchange Commission on Wednesday sued a Massachusetts hedge fund adviser who allegedly drove down the price of San Diego-based Ligand Pharmaceuticals Inc. and bet against its stock to reap more than $1.3 million.

  • September 12, 2018

    Medline's Docs Not False, Judge Says In Catheter Design Row

    Medline Industries Inc. in its patent infringement suit against C.R. Bard Inc. dodged counterclaims that its attorneys acted inequitably during prosecution of the patents at issue after an Illinois federal judge ruled Tuesday that documents Bard called false were not, and the company didn’t prove Medline’s attorneys intended to defraud the U.S. Patent and Trademark Office.

  • September 12, 2018

    Law Schools Struggle To Find Themselves In Post-Recession Market

    Classes on blockchain and artificial intelligence. Crash courses in business and financial markets. These are a few ways law schools are preparing students for a job market that is struggling in the wake of the recession.

  • September 12, 2018

    Bausch Health, Actavis Strike Deal Over Generic Xifaxan

    Bausch Health has agreed to settle all litigation with Teva-owned Actavis over the antibiotic drug Xifaxan, with the generics maker agreeing to hold off until 2028 to release a knockoff version of the gastrointestinal medication, the drug owner announced Wednesday.

  • September 12, 2018

    Intuitive Surgical Investors Strike $42.5M Stock-Drop Deal

    A class of investors in Intuitive Surgical Inc. told a California federal court on Tuesday that it has reached a $42.5 million settlement with the biomedical company over allegations that it misled shareholders about the safety of its “da Vinci” robotic surgery.

  • September 12, 2018

    Conflict Should DQ Katten In IP Row, Valeant Tells Fed. Circ.

    Katten Muchin Rosenman LLP should be disqualified from three ongoing drug patent appeals, Valeant Pharmaceuticals International Inc. told a Federal Circuit panel Wednesday, arguing that when the firm hired two Alston & Bird LLP attorneys and picked up their work for Mylan Pharmaceuticals Inc., it created a fatal conflict.

  • September 12, 2018

    McDermott Snags Ex-HHS OIG Pro As Partner For DC Office

    McDermott Will & Emery LLP has announced a former U.S. Department of Health and Human Services Office of Inspector General senior counselor has joined as a partner to build upon the firm’s health industry advisory practice.

  • September 12, 2018

    Medical Co. Investors Want Final $5M Deal OK'd In IPO Row

    A California federal judge has been asked to give the final approval to a $5 million deal to settle securities claims against medical device company Avinger Inc., which was accused of hiding issues with a signature product in connection with a January 2015 initial public offering. 

  • September 12, 2018

    1st Circ. Questions BioChemics Strategy In SEC Probe Case

    The First Circuit prodded BioChemics Inc. on what it felt was an inconsistent argument Wednesday as the pharmaceutical company tried to flip a district court order denying coverage by Axis Reinsurance Co. for defending against a U.S. Securities and Exchange Commission investigation and enforcement action.

  • September 11, 2018

    How A 'Lost Generation' Of Associates Bounced Back

    Caught in a whirlwind of firm dissolutions and layoffs, thousands of associates were thrust into one of the worst job markets in history a decade ago. While some have rebounded, others are still feeling the lingering effects of the financial crisis on their careers.

  • September 11, 2018

    CRISPR Patent Ruling May Push Warring Sides To A Deal

    The Federal Circuit’s decision Monday rejecting the University of California’s efforts to secure control over patents on the breakthrough gene-editing system CRISPR in a fight with the Broad Institute leaves an unsettled patent landscape for the technology that could spur the parties to strike a deal, attorneys say.

  • September 11, 2018

    Hospitals Sue HHS For Slow-Walking 340B Penalties

    Hospital groups on Tuesday sued the U.S. Department of Health and Human Services in D.C. federal court for not penalizing drugmakers for excess charges in the 340B drug discount program, arguing that a 30-month delay in enforcement is unlawful.

  • September 11, 2018

    Out-Of-State J&J Talc Suits Tossed From Delaware Courts

    A Delaware judge overseeing 200 suits alleging Johnson & Johnson’s talcum powder products cause ovarian cancer on Monday dismissed all of the suits brought by out-of-state plaintiffs, ruling J&J’s selling talc in Delaware isn’t enough for the state court to have jurisdiction in the wake of the U.S. Supreme Court’s Bristol-Myers Squibb ruling.

  • September 11, 2018

    OTC Health Products Maker Hits Ch. 11 In Wake Of Recalls

    Florida-based over-the-counter health care manufacturer Product Quest Manufacturing LLC has filed for Chapter 11 and plans to wind down operations, saying the recall of more than a dozen products last month dealt it a fatal blow after a year of regulatory and financial problems.

  • September 11, 2018

    FDA Warning Wire: Plant Problems Behind Medtronic Recalls

    Recalled Medtronic cardiac defibrillators were at the heart of two warning letters handed out by the U.S. Food and Drug Administration. The agency also cited presurgical swabs with iffy sterility made by a Chinese drugmaker and leaking drug products made by a Canadian company, and continued its crackdown on controversial kratom products. Here's what's new on the FDA enforcement beat.

Expert Analysis

  • Amgen Shows New Patents Can Affect Prior BPCIA Litigation

    Ashley Mays-Williams

    Amgen's third lawsuit against Apotext illustrates how biologic drug owners can use later-issued patents to extend biosimilar litigation after an initial Biologics Price Competition and Innovation Act action has concluded, say attorneys at Paul Hastings LLP.

  • Opinion

    Open The Federal Courthouses

    David Oscar Markus

    Forget about cameras, reporters in the Manafort trial were not even permitted in the courtroom with their phones, tablets or computers. That meant no live reporting on Twitter and no emails to the newsrooms with updates. In a world focused on information and news as it happens, this is unacceptable, says trial attorney David Oscar Markus.

  • 7th Circ. Focuses On Impossibility Preemption In Dolin V. GSK

    William Essig

    The Seventh Circuit’s recent opinion in Dolin v. GlaxoSmithKline largely focused on GSK's argument that federal law preempted any suicidality warning requested by the plaintiff, and notably did not address innovator liability issues relating to Illinois law, says William Essig of Drinker Biddle & Reath LLP.

  • Opinion

    Incorporating Docs By Reference: New 9th Circ. Law Is Flawed

    Brian Sutherland

    In Khoja v. Orexigen Therapeutics, the Ninth Circuit recently concluded that it needed to address “overuse” of documents incorporated by reference in securities cases. But the cure may be worse than the disease, say Brian Sutherland and James Martin of Reed Smith LLP.

  • Payors Share Some Responsibility For The Opioid Epidemic

    Joy Stephenson-Laws

    Recently, well-known commercial insurance companies and government health insurance programs like Medicare and Medicaid have come under scrutiny for their role in allegedly getting and keeping patients addicted to opioid painkillers while not doing enough to help curb the epidemic, says Joy Stephenson-Laws of Stephenson Acquisto and Colman.

  • Brexit: Bracing For A No-Deal Scenario

    Ross Denton

    Once considered the “cliff edge,” the possibility of the United Kingdom exiting from the European Union without agreeing on a trade deal has moved from unthinkable to increasingly likely. Both sides are ramping up preparations for a no-deal scenario, which would have significant implications for businesses in all sectors, say attorneys with Baker McKenzie LLP.

  • Fed. Circ. Clarifies Enablement Requirement In LED Case

    Scott Bornstein

    Last month, the Federal Circuit issued a potentially far-reaching opinion on the application of enablement. The decision in Boston University v. Everlight provides guidance for patentees and patent litigants when initially filing their patent application and later during litigation, say Scott Bornstein and Jonathan Wise of Greenberg Traurig LLP.

  • In SDNY, Indicting Politicians Is The New Black

    Andrew Bauer

    The indictment earlier this month of U.S. Rep. Christopher Collins, R-N.Y., on insider trading charges is the latest in a series of prosecutions that demonstrate the Southern District of New York's growing effort to hold accountable those who take advantage of their influence for improper gain, say attorneys with Arnold & Porter.

  • 'High Availability' — A Key Term In Law Firm IT Strategy

    Jeff Norris

    While most law firm executives and partners may instinctively want to tune out terms like "high availability" and "disaster recovery" — concepts that IT managers usually worry about — there are five reasons you should lean in and wrestle with the vocabulary, say Jeff Norris of Managed Technology Services LLC and Greg Inge of information security consulting firm CQR.

  • The 'Post-Fact' Jury In The 'Fake News' Era

    Ross Laguzza

    The "fake news" phenomenon is ever more prominent in the political arena — but not in the jury box. At a trial, jurors don’t have to rely on the media or any other source to tell them the facts and issues, since they have a front-row seat to the action, says Ross Laguzza, a consultant at R&D Strategic Solutions LLC.